Jan 16 2009
Advanced Medical Optics, Inc. (AMO) (NYSE:EYE), the global leader in advanced refractive technologies for eye care professionals and patients, today announced U.S. Food and Drug Administration (FDA) approval of the TECNIS® Multifocal intraocular lens (IOL) for cataract patients.
The TECNIS® Multifocal IOL’s unique design gives patients superior near vision and reading speed compared to other presbyopia-correcting IOLs, as well as exceptionally high spectacle independence, with nearly 9 out of 10 patients reporting that they never wear glasses after surgery.
Other features/benefits include:
- high-quality vision for near, far and intermediate distances, day or night;
- first and only pupil-independent, non-apodized fully diffractive aspheric lens designed to correct the two highest order aberrations – spherical and chromatic – to give patients back their youthful vision;
- 95 percent patient satisfaction – the highest of any presbyopia-correcting IOL.
“The TECNIS® Multifocal IOL delivers a predictable and consistent full range of vision,” said Ralph Chu, M.D., founder and director of the Chu Vision Institute in Bloomington, Minn. “The U.S. clinical study shows that more than 94 percent of patients function comfortably without glasses for all distances, including intermediate. More importantly, my own patients are highly satisfied with the results.”
“The full diffractive surface of the TECNIS® Multifocal IOL provides high-quality vision largely independent of pupil size and reduces chromatic aberration for better image quality,” said Manfred Tetz, M.D., professor of ophthalmology and director of Eye-Center-Spreebogen, Berlin, Germany. “I have been implanting the TECNIS® Multifocal IOL since 2003 because of the high-quality visual results that I can provide for my patients, who report being extremely satisfied with their vision.”
“The introduction of the TECNIS® Multifocal IOL in the U.S. rounds out AMO’s portfolio of market-leading, refractive technologies,” said AMO Chairman and CEO Jim Mazzo. “Following years of success in Europe, U.S. surgeons will soon be able to pass the benefits of this technology on to their patients.”
TECNIS® Multifocal IOLs are indicated for primary implantation for the visual correction of aphakia in adult patients with and without presbyopia in whom a cataractous lens has been removed by phacoemulsification and who desire near, intermediate, and distance vision with increased spectacle independence. The IOLs are intended to be placed in the capsular bag.
AMO plans to ship TECNIS® Multifocal IOLs to U.S. surgeons in early 2009.